Hoffmann-la Roche Company Profile
✉ Email this page to a colleague
What is the competitive landscape for HOFFMANN-LA ROCHE, and what generic alternatives to HOFFMANN-LA ROCHE drugs are available?
HOFFMANN-LA ROCHE has two approved drugs.
There are four US patents protecting HOFFMANN-LA ROCHE drugs.
There are one hundred and seven patent family members on HOFFMANN-LA ROCHE drugs in thirty-eight countries and twenty-one supplementary protection certificates in sixteen countries.
Summary for Hoffmann-la Roche
| International Patents: | 107 |
| US Patents: | 4 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
| Patent Litigation for Hoffmann-la Roche: | See patent lawsuits for Hoffmann-la Roche |
Drugs and US Patents for Hoffmann-la Roche
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hoffmann-la Roche | ALECENSA | alectinib hydrochloride | CAPSULE;ORAL | 208434-001 | Dec 11, 2015 | RX | Yes | Yes | 10,350,214 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Hoffmann-la Roche | ALECENSA | alectinib hydrochloride | CAPSULE;ORAL | 208434-001 | Dec 11, 2015 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | |||||
| Hoffmann-la Roche | ALECENSA | alectinib hydrochloride | CAPSULE;ORAL | 208434-001 | Dec 11, 2015 | RX | Yes | Yes | 9,365,514 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Hoffmann-la Roche | ALECENSA | alectinib hydrochloride | CAPSULE;ORAL | 208434-001 | Dec 11, 2015 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Hoffmann-la Roche
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Hoffmann-la Roche | INVIRASE | saquinavir mesylate | TABLET;ORAL | 021785-001 | Dec 17, 2004 | 5,196,438*PED | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Hoffmann-la Roche Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Taiwan | 201622706 | See Plans and Pricing |
| Japan | WO2015163448 | See Plans and Pricing |
| Singapore | 11201607623X | See Plans and Pricing |
| Australia | 2020230293 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Hoffmann-la Roche Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2441753 | C02441753/01 | Switzerland | See Plans and Pricing | PRODUCT NAME: ALECTINIBUM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65970 26.01.2017 |
| 0432695 | 32/1996 | Austria | See Plans and Pricing | PRODUCT NAME: SAQUINAVIR UND SEINE SAEUREADDITIONSSALZE, INSBESONDERE SAQUINAVIRMESYLAT; REGISTRATION NO/DATE: EU/1/96/026/001 19961004 |
| 2441753 | SPC/GB17/036 | United Kingdom | See Plans and Pricing | PRODUCT NAME: ALECTINIB (9-ETHYL-6,6-DIMETHYL-8-(4-MORPHOLIN-4-YL-PIPERIDIN-1-YL)-11-OXO-6,11-DIHYDRO-5H-BENZO(B)CARBAZOLE-3-CARBONITRILE) OR A SALT OR SOLVATE THEREOF; REGISTERED: UK EU/1/16/1169 (NI) 20170220; UK PLGB 00031/0843 20170220 |
| 2441753 | PA2017017,C2441753 | Lithuania | See Plans and Pricing | PRODUCT NAME: ALEKTINIBAS ARBA JO DRUSKA, ARBA SOLVATAS; REGISTRATION NO/DATE: EU/1/16/1169 20170216 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
